Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocrystalline Megestrol in ES-SCLC Cachexia
NCT06793228Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of megestrol in cancer cachexia (4 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Proportion of weight increase relative to baseline > 5% at 12 weeks. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
megestrol
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT06793228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793228.